Researchers found that patients with glioblastoma multiforme treated with radiation and chemotherapy drug temozolomide can live up to four years after diagnosis, compared to three percent of those who received only radiation. The treatment has become the standard for GBM patients worldwide.
A new study found that a combination of bevacizumab (Avastin) and chemotherapy may increase survival time for patients with glioblastoma multiforme, a deadly type of brain tumor. The treatment showed promising results in improving outcomes for patients who have already been diagnosed with the disease.
MIT scientists have discovered a connection between two proteins found in brain tumors that could help treat glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Attacking both EGFRvIII and c-Met simultaneously is more effective than targeting either protein alone, offering new hope for treating this deadly disease.
Researchers found vorinostat's anti-cancer activity in patients with recurrent glioblastoma multiforme, with a 15% patient success rate and improved median overall survival. The study aimed to explore the novel application of vorinostat in targeting brain cancer.
The Novo-TTF device has been shown to disrupt tumor growth by interfering with cell division of cancerous cells, causing them to stop proliferating and die off. In a pilot trial, 10 patients with recurring GBM experienced improved survival rates, with median overall survival doubling compared to historical data.
Researchers have discovered a new class of genetic mutations in the EGFR gene that occur in glioblastoma, a deadly type of brain tumor. These mutations, located in the extracellular domain of the protein, can activate oncogenically EGFR, making them a potential target for cancer therapy.
Mayo Clinic Cancer Center is conducting a clinical study using a vaccine strain of the measles virus to treat recurrent glioblastoma multiforme, a deadly brain tumor. The study has shown promising results in shrinking tumors and prolonging animal survival.
Gliadel Wafer demonstrates long-term survival benefit for patients with high-grade malignant glioma, increasing median survival to 13.9 months from 11.6 months. The treatment also shows a significant reduction in risk of death over the study period, with a 27% lower risk compared to placebo.
Glioblastoma multiforme, the most common adult brain cancer, has a median survival of about one year after diagnosis. Researchers have identified EGFR as a target for therapeutic drugs, offering new hope for patients. The study found that targeting both mutant and normal EGFR can destroy brain cancer cells while sparing healthy ones.
Researchers have discovered a new radiotherapy technique using gadolinium to treat glioblastoma (GBM) with minimal invasiveness. The therapy, called Gadolinium Synchrotron Stereotactic Radiotherapy (GdSSR), targets cancer cells while sparing normal brain tissue, offering a potential cure for this deadly disease.
Researchers at UCLA have identified a molecular signature that can predict which patients with glioblastoma, a deadly brain cancer, are likely to respond to drug therapy. The discovery involves the presence of a mutant protein and a tumor suppressor protein called PTEN.
Researchers identified EGFRvIII and PTEN proteins as key factors in determining tumor response to EGFR inhibitors. These findings suggest that adjusting treatment based on genetic activity could significantly prolong life for glioblastoma patients and prevent unnecessary treatments.
Researchers developed a large brain tumor model and tested a genetically engineered virus delivering two proteins to the brain. The findings show that combined RAdTK and RAdFlt3L gene therapy eliminated glioblastoma multiforme in lab rats, increasing survival rates significantly.
Researchers at Mayo Clinic have developed a new treatment for recurrent glioblastoma multiforme, a form of adult brain cancer with dismal prognosis. The 'smart' drug CCI-779 showed significant response in 36 percent of patients, suggesting potential improvement in treatment outcomes.
A study of 301 patients with glioblastoma multiforme found that the 'SS' variant genotype of hTERT significantly improved survival rates, averaging 25 months compared to 14 months for other genotypes. The research suggests new treatment directions for this aggressive cancer.
Researchers at Cedars-Sinai Medical Center found that a genetically engineered virus delivering the protein hsFlt3L slowed tumor growth and increased immune cell production in laboratory rats with glioblastoma multiforme. The study may lead to a new treatment approach for patients with GBM.
Researchers at Cedars-Sinai Medical Center found that combining an anti-tumor vaccine with chemotherapy significantly extended patient survival to 26 months on average. The treatment, which involves dendritic-cell immunotherapy, was shown to slow tumor growth and increase the effectiveness of chemotherapy.
A phase III study uses IL13-PE38QQR, a hybrid protein that attaches to specific receptors on tumor cells, to target residual GBM brain tumors. The treatment, convection-enhanced delivery, facilitates infusion of the drug into the brain, bypassing the blood-brain barrier.
Cedars-Sinai researchers found that laminin-8 expression is linked to tumor aggressiveness and patient outcomes. High levels of laminin-8 are associated with shorter survival times and increased risk of tumor recurrence.
Scientists at Cedars-Sinai Medical Center used gene array technology to analyze thousands of genes in malignant brain tumor samples. They identified a critical step in the development of glioblastoma multiforme, which may improve patient prognosis and lead to effective therapies.
Researchers at Penn State's College of Medicine have identified a marker for certain types of brain tumors, including glioblastoma multiforme (GBM), which are the most prevalent and difficult-to-manage. The marker, interleukin 13 receptor, is present in over 90% of patients with GBM, making it a valuable diagnostic tool.
Researchers at Thomas Jefferson University are conducting a gene therapy trial for glioblastoma, a form of brain cancer. The trial aims to delay disease progression and improve quality of life for patients, offering a potential cure for the deadliest type of brain tumor.